Illinois Gastroenterology Group, PLLC faces a proposed class action in the wake of an October 2021 data breach during which patients’ sensitive personal information was reportedly exposed to unauthorized access. According to the 31-page lawsuit, the breach was a direct result of the physicians’ group’s failure to adequately safeguard the information with which it was entrusted. The suit says the exposed data included consumers’ names; addresses; dates of birth; Social Security, driver’s license and passport numbers; financial account and payment card information; employee IDs, medical information and biometric data.
Author: Praveen Suthrum
Results from a double-blind, randomized OPT-PEACE trial showed that almost all patients (at low bleeding risk) who received antiplatelet therapy developed a gastrointestinal injury, although overt bleeding was infrequent. Further, it was found that dual antiplatelet therapy (DAPT) followed by Single Antiplatelet Therapy (SAPT) versus continued DAPT resulted in less GI injury…
MADISON, Wis., April 26, 2022 /PRNewswire/ — Exact Sciences Corp. ( Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021. “The Exact Sciences team delivered outstanding results to start 2022, testing a record number of people with Cologuard® and Oncotype DX®,” said Kevin Conroy, chairman and CEO. “We plan to fundamentally change the way cancer is diagnosed and treated, powered by our strong foundation in cancer screening and precision oncology, our deep pipeline of innovative tests, and a clear path to sustainable, profitable growth.”
In this episode, Peter and I discuss the birth and development of Odin vision, details on the future of AI in GI and how Odin Vision differentiates itself from other AI companies in the GI field.
AGA is proud to announce the 61 recipients selected to receive research funding through its annual AGA Research Foundation Awards Program. The program serves as a catalyst for discovery and career growth among the most promising researchers in gastroenterology and hepatology. “Our award recipients demonstrate an undeniable determination to improve the care of digestive health patients,” said Robert S. Sandler, MD, MPH, AGAF, chair, AGA Research Foundation. “We are investing in talented early career investigators knowing that their work will ultimately benefit patients with critical needs.”
The US Preventive Services Task Force (USPSTF) has backtracked on low-dose aspirin for the prevention of colorectal cancer (CRC), stating in new guidance that the evidence is too murky to make a recommendation either for or against it. The group dialed back from its 2016 recommendation because new findings from a handful of trials mean that the evidence is now “unclear whether aspirin use reduces the risk of CRC cancer incidence or mortality.”
DALLAS, May 5, 2022 /PRNewswire/ — GI Alliance, the nation’s largest independent gastroenterology practice, is pleased to announce a partnership with Gastroenterology Consultants, expanding GI Alliance’s greater Houston area locations. Gastroenterology Consultants consists of nine physicians and six advanced practice providers who provide GI care in six locations. Offices are in Ellington, St. John (Nassau Bay), Pasadena, Pearland, Clear Lake (Webster), and League City.
Artificial intelligence has the potential to become a money-saving industry standard in gastroenterology. Austin Chiang, MD, chief medical officer of gastrointestinal at Medtronic, spoke with Becker’s on April 29 to discuss how AI could be the next cost-effective industry standard for detection. Editor’s note: Responses have been lightly edited for length and clarity.
PALO ALTO, Calif.–(BUSINESS WIRE)– Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC). The test, which only requires patients to complete a simple blood draw, is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for CRC.
According to the hospital, the most effective treatment for metastatic colorectal cancer is targeted therapy and chemotherapy, which block only a specific gene with a mutation. However, some patients show a mixed response, developing tolerance in only a few lesions during treatment. While it is common to change the anticancer drug in such cases, there is a limit as the changed drug may have lower efficacy than the original drug and reduce available drugs for the patient